keyword
MENU ▼
Read by QxMD icon Read
search

lung cancer bone metastasis

keyword
https://www.readbyqxmd.com/read/29146616/therapeutic-potential-of-afatinib-for-cancers-with-erbb2-her2-transmembrane-domain-mutations-g660d-and-v659e
#1
Hiromasa Yamamoto, Shinichi Toyooka, Takashi Ninomiya, Shigemi Matsumoto, Masashi Kanai, Shuta Tomida, Katsuyuki Kiura, Manabu Muto, Ken Suzawa, Patrice Desmeules, Mark G Kris, Bob T Li, Marc Ladanyi
We previously reported on a family with hereditary lung cancer, in which a germline mutation in the transmembrane domain (G660D) of avian erythroblastic leukemia viral oncogene homolog 2 (erb-b2 receptor tyrosine kinase 2) (ERBB2; human epidermal growth factor receptor 2 [HER2]) seemed to be responsible for the cancer predisposition. Although few data are available on treatment, anti-ERBB2 therapeutic agents may be effective for ERBB2-mutant cancers. The familial lung cancer patient in one of the authors' institutes developed bone metastasis with enlarging lung tumors and was treated with the ERBB2 inhibitor afatinib...
November 16, 2017: Oncologist
https://www.readbyqxmd.com/read/29135778/accuracy-of-medicare-claim-based-algorithm-to-detect-breast-prostate-or-lung-cancer-bone-metastases
#2
Nalini Sathiakumar, Elizabeth Delzell, Huifeng Yun, Rene Jooste, Kelly Godby, Carla Falkson, Mellissa Yong, Meredith L Kilgore
BACKGROUND: We had previously developed an algorithm for Medicare claims data to detect bone metastases associated with breast, prostate, or lung cancer. This study was conducted to examine whether this algorithm accurately documents bone metastases on the basis of diagnosis codes in Medicare claims data. METHODS: We obtained data from Medicare claims and electronic medical records of patients 65 years or older with a breast, prostate, or lung cancer diagnosis at a teaching hospital and/or affiliated clinics during 2005 or 2006...
December 2017: Medical Care
https://www.readbyqxmd.com/read/29133416/rsk2-phosphorylates-t-bet-to-attenuate-colon-cancer-metastasis-and-growth
#3
Ke Yao, Cong Peng, Yuwen Zhang, Tatyana A Zykova, Mee-Hyun Lee, Sung-Young Lee, Enyu Rao, Hanyong Chen, Joohyun Ryu, Lei Wang, Yi Zhang, Ge Gao, Wei He, Wei-Ya Ma, Kangdong Liu, Ann M Bode, Ziming Dong, Bing Li, Zigang Dong
Metastasis is a major cause of cancer-related deaths. Approximately 80% of patients with colorectal cancer develop liver metastasis and 20% develop lung metastasis. We found that at different stages of colon cancer, IFNγ secretion from peripheral blood mononuclear cells was decreased compared with healthy controls. The ribosomal S6 kinase (RSK) family of kinases has multiple cellular functions, and we examined their roles in this observed IFNγ decrease. Flow cytometry analysis of wild-type (WT) and RSK2 knockout (KO) mice revealed significantly lower levels of IFNγ in the RSK2 KO mice compared with the WT mice...
November 13, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/29115583/unfavorable-effect-of-calcitriol-and-its-low-calcemic-analogs-on-metastasis-of-4t1-mouse-mammary-gland-cancer
#4
Artur Anisiewicz, Agata Pawlik, Beata Filip-Psurska, Eliza Turlej, Stanisław Dzimira, Magdalena Milczarek, Katarzyna Gdesz, Diana Papiernik, Joanna Jarosz, Dagmara Kłopotowska, Andrzej Kutner, Andrzej Mazur, Joanna Wietrzyk
Low vitamin D status is considered as a risk factor for breast cancer and has prognostic significance. Furthermore, vitamin D deficiency increases after adjuvant cancer therapy, which alters bone metabolism increasing the risk of osteoporosis. It is now postulated that vitamin D supplementation in breast cancer treatment delays the recurrence of cancer thereby extending survival. We evaluated the impact of calcitriol and its low-calcemic analogs, PRI‑2191 and PRI‑2205, on the tumor growth, angiogenesis, and metastasis of 4T1 mouse mammary gland cancer...
November 2, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/29113396/epidermal-growth-factor-receptor-is-associated-with-the-onset-of-skeletal-related-events-in-non-small-cell-lung-cancer
#5
Shu-Mei Huang, Jin-Ji Yang, Hua-Jun Chen, Si-Pei Wu, Xiao-Yan Bai, Qing Zhou, Hai-Yan Tu, Yi-Long Wu
Background: Bone metastasis and skeletal related events (SREs) are common in non-small cell lung cancer (NSCLC). Patients with mutant epidermal growth factor receptor (EGFR) could benefit from tyrosine kinase inhibitors (TKIs). However, it is unclear whether SRE is influenced by EGFR status. We aimed to evaluate the correlation of EGFR status and TKIs with the incidence of SREs. Methods: We conducted a retrospective study of stage IV NSCLC patients with bone metastasis...
October 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/29113190/predictors-of-egfr-mutation-and-factors-associated-with-clinical-tumor-stage-at-diagnosis-experience-of-the-insight-study-in-poland
#6
Rodryg Ramlau, Paweł Krawczyk, Rafał Dziadziuszko, Izabela Chmielewska, Janusz Milanowski, Włodzimierz Olszewski, Katarzyna Stencel, Katarzyna Ramlau-Piątek, Agnieszka Segiet, Michał Skroński, Jacek Grudny, Joanna Chorostowska-Wynimko
Targeted therapy of non-small cell lung cancer (NSCLC) patients with mutations in the epidermal growth factor receptor (EGFR) gene has been associated with improved prognosis. However, there is a shortage on data from real-world clinical practice in management of EGFR-positive NSCLC patients in Poland. The present study retrospectively analyzed data from the INSIGHT study to evaluate the incidence and clinical management of EGFR-positive NSCLC in Poland. The authors additionally aimed to identify predictors of the EGFR mutation and factors associated with clinical stage of the tumor at diagnosis...
November 2017: Oncology Letters
https://www.readbyqxmd.com/read/29110845/an-international-epidemiological-analysis-of-young-patients-with-non-small-cell-lung-cancer-adujov-clicap
#7
Luis Corrales-Rodríguez, Oscar Arrieta, Luis Mas, Renata Báez-Saldaña, Omar Castillo-Fernández, Normand Blais, Claudio Martín, Melissa Juárez, Priyanka Khanna, Allan Ramos-Esquivel, Ludwing Bacon, Leonardo Rojas, Beatriz Wills, George Oblitas, María Angelina Pérez, Mauricio Cuello, Andrés Felipe Cardona
BACKGROUND: A proportion of patients with NSCLC is diagnosed at 40 years or younger. These patients tend to be never-smokers, usually present with stage IV adenocarcinoma, and have somatic genomic alterations. Few studies have documented and analyzed epidemiological characteristics of this population. MATERIALS AND METHODS: We performed an international epidemiological analysis of 389 young patients with NSCLC. Data was collected from centers participating in the Latin American Consortium for Lung Cancer Research (AduJov-CLICaP)...
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29109795/the-use-of-pet-imaging-for-prognostic-integrin-%C3%AE-2%C3%AE-1-phenotyping-to-detect-non-small-cell-lung-cancer-and-monitor-drug-resistance-responses
#8
Chiun-Wei Huang, Wen-Chuan Hsieh, Shih-Ting Hsu, Yi-Wen Lin, Yi-Hsiu Chung, Wen-Chi Chang, Han Chiu, Yun Han Lin, Chung-Pu Wu, Tzu-Chen Yen, Feng-Ting Huang
PURPOSE: Growing evidence has demonstrated that aberrant expression of integrin α2β1 might contribute to the invasion, metastasis and drug resistance of non-small cell lung cancer (NSCLC). Thus, the integrin α2β1 targeting (68)Ga-DOTA-A2B1 tracer was validated in NSCLC in contrast to accumulation of the clinically used (18)F-FDG PET tracer to see if (68)Ga-DOTA-A2B1-PET imaging can offer a valuable and critical diagnostic imaging criterion for the identification of phenotypes of aggressive lung cancer...
2017: Theranostics
https://www.readbyqxmd.com/read/29105655/pre-metastatic-cancer-exosomes-induce-immune-surveillance-by-patrolling-monocytes-at-the-metastatic-niche
#9
Michael P Plebanek, Nicholas L Angeloni, Elena Vinokour, Jia Li, Anna Henkin, Dalia Martinez-Marin, Stephanie Filleur, Reshma Bhowmick, Jack Henkin, Stephen D Miller, Igal Ifergan, Yesung Lee, Iman Osman, C Shad Thaxton, Olga V Volpert
Metastatic cancers produce exosomes that condition pre-metastatic niches in remote microenvironments to favor metastasis. In contrast, here we show that exosomes from poorly metastatic melanoma cells can potently inhibit metastasis to the lung. These "non-metastatic" exosomes stimulate an innate immune response through the expansion of Ly6C(low) patrolling monocytes (PMo) in the bone marrow, which then cause cancer cell clearance at the pre-metastatic niche, via the recruitment of NK cells and TRAIL-dependent killing of melanoma cells by macrophages...
November 6, 2017: Nature Communications
https://www.readbyqxmd.com/read/29101110/the-biology-of-bone-metastasis
#10
Mark Esposito, Theresa Guise, Yibin Kang
Bone metastasis, or the development of secondary tumors within the bone of cancer patients, is a debilitating and incurable disease. Despite its morbidity, the biology of bone metastasis represents one of the most complex and intriguing of all oncogenic processes. This complexity derives from the intricately organized bone microenvironment in which the various stages of hematopoiesis, osteogenesis, and osteolysis are jointly regulated but spatially restricted. Disseminated tumor cells (DTCs) from various common malignancies such as breast, prostate, lung, and kidney cancers or myeloma are uniquely primed to subvert these endogenous bone stromal elements to grow into pathological osteolytic or osteoblastic lesions...
November 3, 2017: Cold Spring Harbor Perspectives in Medicine
https://www.readbyqxmd.com/read/29100297/cancer-associated-fibroblasts-enhance-metastatic-potential-of-lung-cancer-cells-through-il-6-stat3-signaling-pathway
#11
Limin Wang, Limin Cao, Huimin Wang, Boning Liu, Qicheng Zhang, Zhaowei Meng, Xiang Wu, Qinghua Zhou, Ke Xu
Recent studies indicate that cancer-associated fibroblasts (CAFs) are involved in tumor growth, invasion and metastasis, however, the underling mechanisms remain unclear. In the present study, we investigated the role of CAFs on the metastatic potential of lung cancer cells. The stromal fibroblasts we isolated from lung cancer tissues presented CAFs characteristics with high levels of α-smooth muscle actin (α-SMA) and fibroblast-activating protein (FAP). Our data showed that the conditioned medium from cultured CAFs (CAF-CM) dramatically enhanced migration and invasion of lung cancer cells...
September 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/29095550/downregulation-of-cd24-suppresses-bone-metastasis-of-lung-cancer
#12
Hinako Okabe, Katsuhiko Aoki, Satomi Yogosawa, Mitsuru Saito, Keishi Marumo, Kiyotsugu Yoshida
Suppression of bone metastasis can improve patient quality of life. Current drugs for bone metastasis have been shown to prolong progression-free survival but not overall survival; therefore, other potential therapeutic targets for bone metastasis should be investigated. Cell-surface antigens, such as CD24, have been recently shown to be involved in the metastasis of various cancers. However, whether CD24 plays a role in bone metastasis of lung cancer remains unknown. To observe metastasis of lung cancer cells by imaging technology, we introduced a near-infrared fluorescent protein, iRFP720, into a bone-seeking subclone established from lung cancer cells, HARA-B4 cells...
November 2, 2017: Cancer Science
https://www.readbyqxmd.com/read/29070650/interleukin-12-from-cd103-batf3-dependent-dendritic-cells-required-for-nk-cell-suppression-of-metastasis
#13
Deepak Mittal, Dipti Vijayan, Eva M Putz, Amelia R Aguilera, Kate A Markey, Jasmin Straube, Stephen Kazakoff, Stephen L Nutt, Kazuyoshi Takeda, Geoffrey R Hill, Nicola Waddell, Mark J Smyth
Several host factors may affect the spread of cancer to distant organs, however the intrinsic role of dendritic cells (DCs) in controlling metastasis is poorly described. Here we show in several tumor models that although the growth of primary tumors in Batf3-deficient mice, which lack cross-presenting DCs, was not different from primary tumors in wild-type (WT) control mice, Batf-deficient mice had increased experimental and spontaneous metastasis and poorer survival. The increased metastasis was independent of CD4+ and CD8+ T lymphocytes, but required NK cells and IFNγ...
October 25, 2017: Cancer Immunology Research
https://www.readbyqxmd.com/read/29069785/-10-gingerol-induces-apoptosis-and-inhibits-metastatic-dissemination-of-triple-negative-breast-cancer-in-vivo
#14
Ana Carolina B M Martin, Angelina M Fuzer, Amanda B Becceneri, James Almada da Silva, Rebeka Tomasin, Delphine Denoyer, Soo-Hyun Kim, Katherine A McIntyre, Helen B Pearson, Belinda Yeo, Aadya Nagpal, Xiawei Ling, Heloisa S Selistre-de-Araújo, Paulo Cézar Vieira, Marcia R Cominetti, Normand Pouliot
There is increasing interest in the use of non-toxic natural products for the treatment of various pathologies, including cancer. In particular, biologically active constituents of the ginger oleoresin (Zingiber officinale Roscoe) have been shown to mediate anti-tumour activity and to contribute to the anti-inflammatory, antioxidant, antimicrobial, and antiemetic properties of ginger. Here we report on the inhibitory properties of [10]-gingerol against metastatic triple negative breast cancer (TNBC) in vitro and in vivo...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29066702/-two-cases-in-which-eribulin-mesylate-was-effective-for-taxane-resistant-advanced-breast-cancer
#15
Keita Adachi, Shuhei Suzuki, Hitomi Kubota, Yukiko Hara, Asako Fujiwara, Eiko Waga, Tomohiro Hirano, Katsuhisa Enomoto, Kenichi Sakurai, Makoto Makishima, Tsugumichi Koshinaga
We experienced 2 cases in which eribulin mesylate was effective for taxane-resistant advanced breast cancer. Case 1: A 65- year-old woman was diagnosed with advanced breast cancer(T4cN2aM0, stage III B)and treated with chemotherapy(nabpaclitaxel). Bone metastasis was observed; then, she sequentially received epirubicin and cyclophosphamide, nab-paclitaxel, and bevacizumab and paclitaxel. However, lung metastases appeared, and we changed the regimen to eribulin mesylate. We administered 11 courses of eribulin mesylate before bone marrow metastasis appeared...
October 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29066121/patterns-of-intraosseous-recurrence-after-stereotactic-body-radiation-therapy-for-coxal-bone-metastasis
#16
Kei Ito, Takuya Shimizuguchi, Keiji Nihei, Tomohisa Furuya, Hiroaki Ogawa, Hiroshi Tanaka, Keisuke Sasai, Katsuyuki Karasawa
PURPOSE: To analyze the detailed pattern of intraosseous failure after stereotactic body radiation therapy (SBRT) for coxal bone metastasis. METHODS AND MATERIALS: Patients treated with SBRT to coxal bone metastasis were identified by retrospective chart review. The SBRT doses were 30 Gy or 35 Gy in 5 fractions. A margin of 5 to 10 mm was added to the gross tumor volume to create the clinical target volume. We evaluated the presence or absence of intraosseous recurrence using magnetic resonance imaging...
September 5, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29061023/-exploration-of-the-rational-therapeutic-regimen-for-advanced-lung-cancer-patients-with-mild-tumor-enlargement
#17
X L Zhang, X Y Wang, C C Zhang, J Yang, X H Yuan, K Li
Objective: To investigate the factors that impacts of therapeutic effect in advanced non-small cell lung cancer (NSCLC) patients with mild tumor enlargement and the rational therapeutic strategy for them. Methods: The clinicopathological features and prognostic data of advanced NSCLC patients whose sum of tumor longest diameters with 0 to 20% increase were retrospectively explored, and the Cox proportional hazards model was used to analyze the independent prognostic factors in patients. Results: The median progression-free survival (PFS) of 54 patients with the original regimen was 87 days, significantly less than 168 days of the median PFS of 49 patients with replacing regimen (P<0...
October 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/29049806/results-of-treatment-for-thymic-neuroendocrine-tumours-multicentre-clinicopathological-study
#18
Naoko Ose, Hajime Maeda, Masayoshi Inoue, Eiichi Morii, Yasushi Shintani, Hiroshi Matsui, Hirohito Tada, Tositeru Tokunaga, Kenji Kimura, Yasushi Sakamaki, Yukiyasu Takeuchi, Kenjiro Fukuhara, Hiroshi Katsura, Teruo Iwasaki, Meinoshin Okumura
OBJECTIVES: A thymic neuroendocrine tumour (TNET) is rare, and few comprehensive reports of treatment results have been presented. To clarify the clinicopathological characteristics of TNET in affected patients, outcomes were retrospectively examined using cases accumulated in a multicentre survey. METHODS: Thirty patients (25 men and 5 women) who underwent surgical resection or biopsy procedures at 10 institutions of the Thoracic Surgery Study Group of Osaka University (TSSGO) between January 1986 and June 2015 and pathologically diagnosed with TNET were enrolled...
August 17, 2017: Interactive Cardiovascular and Thoracic Surgery
https://www.readbyqxmd.com/read/29044578/factors-associated-with-local-recurrence-after-surgery-for-bone-metastasis-to-the-extremities
#19
Chandra Kumar Krishnan, Han-Soo Kim, Ji Yeon Yun, Hwan Seong Cho, Jong Woong Park, Ilkyu Han
BACKGROUND AND OBJECTIVES: With increasing life expectancy of patients with bone metastasis, durable surgical stabilization of bone metastasis is necessary. Local recurrence (LR) can compromise surgical stabilization and necessitate retreatment. We analyzed LR rate and factors associated with LR in patients undergoing surgery for bone metastasis. METHODS: Patients (n = 301) who underwent surgery for bone metastasis to the extremities were reviewed. Possible factors that might be associated with LR were investigated...
October 16, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29039564/evaluation-of-microrna-203-in-bone-metastasis-of-patients-with-non-small-cell-lung-cancer-through-tgf-%C3%AE-smad2-expression
#20
Yucheng Wei, Dongmei Li, Dong Wang, Tong Qiu, Kui Liu
This study investigated the regulatory effect of microRNA-203 on bone metastasis of non-small cell lung cancer (NSCLC). Quantitative real-time PCR was used to examine microRNA-203 in tissue specimens of bone metastasis of patients with NSCLC. In bone metastasis of patients with NSCLC, microRNA-203 expression was decreased, compared with control group. We also surveyed overall survival (OS) and disease-free survival (DFS), microRNA-203 high expression in bone metastasis of patients with NSCLC was higher than in those with microRNA-203 low expression...
September 21, 2017: Oncology Reports
keyword
keyword
78719
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"